Skip to content

Eloralintide ResearchScience today. A healthier tomorrow.

Ask the site

Phase 1 eloralintide, Japanese participants (NCT06297616)

Last verified How this was verified

Trial record

Trial name
Phase I, multiple-ascending-dose study in Japanese participants
Registry identifier
NCT06297616
Phase
Phase I
Sponsor
Eli Lilly and Company
Population
Japanese adults with obesity or overweight
Intervention
Eloralintide (LY3841136) alone (Part A) and with tirzepatide (Part B)
Comparator
Placebo (placebo for each drug listed)
Enrollment
128
Study status
Completed (confirmed 2026-10-01 via ClinicalTrials.gov; completed 2025-11-21)
Start date
2024-04-15
Completion date
2025-11-21
Results availability
No results posted on ClinicalTrials.gov as of 2026-10-01

Primary endpoints

  • Primary: treatment-related serious adverse events (Part A to week 22, Part B to week 34). Secondary: eloralintide pharmacokinetics (AUC and Cmax) and change in body weight (Part A at week 12, Part B at week 24) (ClinicalTrials.gov, confirmed 2026-10-01)

Primary registry record

A trial registration shows that a study exists. It does not show that the compound works, is safe, or has been approved, and recruitment says nothing about the eventual result.

This multiple-ascending-dose Phase 1 study examined the safety, tolerability, pharmacokinetics and effects of eloralintide alone, and with tirzepatide, in Japanese people with obesity or overweight. It ran at 3 sites in Japan.

Read with care: A registry record describes a study’s plan and status. It is not a result, and it does not show that the drug works or is safe.

Study context

What the study tests

This Phase 1 multiple-ascending-dose study has two parts and enrolled Japanese adults with obesity or overweight. Part A tests eloralintide (listed as LY3841136) alone and Part B tests it together with tirzepatide, both with placebo controls. The primary endpoints count serious adverse events judged related to the study drug, at week 22 for Part A and week 34 for Part B. The record lists 128 participants.

Who can take part

Adults aged 18 to 65 needed a BMI from 27 to 40, a stable weight and no diabetes. The record excludes any malignancy in the past five years and, for Part B, tirzepatide in the previous six months and a personal or family history of medullary thyroid carcinoma. Sites are in Tokyo and Fukuoka.

What the registry does not say

The study is marked completed, with primary completion on 21 November 2025, and no results are posted. Body weight change is a secondary measure, at week 12 for Part A and week 24 for Part B, so the record is built around safety and drug levels, not efficacy.

Source: ClinicalTrials.gov record NCT06297616, read on 2026-10-15. Registered plans can change.

References

  1. US National Library of Medicine. ClinicalTrials.gov registry records for the eloralintide clinical program. ClinicalTrials.gov. P1